11. Myasthenia gravis Clinical trials / Disease details

Clinical trials : 315 / Drugs : 232 - (DrugBank : 77) / Drug target genes : 46 - Drug target pathways : 126

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04225871 (ClinicalTrials.gov)	December 23, 2019	2/10/2019	Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis	A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis	Generalized Myasthenia Gravis	Drug: zilucoplan (RA101495)	Ra Pharmaceuticals	NULL	Active, not recruiting	18 Years	N/A	All	200	Phase 3	United States;Canada;France;Germany;Italy;Japan;Norway;Poland;Spain;United Kingdom
2	NCT04115293 (ClinicalTrials.gov)	September 17, 2019	2/10/2019	Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis	A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis	Myasthenia Gravis, Generalized	Drug: zilucoplan (RA101495);Drug: Placebo	Ra Pharmaceuticals	NULL	Completed	18 Years	74 Years	All	174	Phase 3	United States;Canada;France;Germany;Italy;Japan;Norway;Poland;Spain;United Kingdom
3	NCT03315130 (ClinicalTrials.gov)	October 11, 2017	16/10/2017	Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects With Generalized Myasthenia Gravis	Generalized Myasthenia Gravis	Drug: zilucoplan (RA101495);Drug: Placebo	Ra Pharmaceuticals	NULL	Completed	18 Years	85 Years	All	44	Phase 2	United States;Canada